menu search

VALN / Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data

Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data
Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults. Read More
Posted: Dec 2 2022, 12:02
Author Name: Zacks Investment Research
Views: 112574

VALN News  

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

By GlobeNewsWire
October 11, 2023

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will pre more_horizontal

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

By GlobeNewsWire
August 31, 2023

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

Saint- Herb lain (France ) , August 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that more_horizontal

Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?

By Zacks Investment Research
June 21, 2023

Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?

Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi more_horizontal

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

By GlobeNewsWire
May 31, 2023

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Saint- Herb lain (France) , May 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its more_horizontal

Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

By Zacks Investment Research
May 30, 2023

Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program. more_horizontal

Valneva SE (VALN) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 6, 2023

Valneva SE (VALN) Q1 2023 Earnings Call Transcript

Valneva SE (NASDAQ:VALN ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - Chair more_horizontal

Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

By GlobeNewsWire
March 30, 2023

Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

Saint Herblain (France), March 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will prese more_horizontal

Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future

By Seeking Alpha
March 29, 2023

Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future

Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial. The CHIKV vaccine c more_horizontal


Search within

Pages Search Results: